Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators.
about
CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcriptionPITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo.Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase IIThe HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase IIStructural determinants and mechanism of HIV-1 genome packagingThe human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzymeMolecular cloning and characterization of a cellular protein that interacts with the human immunodeficiency virus type 1 Tat transactivator and encodes a strong transcriptional activation domainLentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactorThe human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for functionA Tat-induced auto-up-regulatory loop for superactivation of the human immunodeficiency virus type 1 promoterTranscription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitroP-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase IIHuman and rodent transcription elongation factor P-TEFb: interactions with human immunodeficiency virus type 1 tat and carboxy-terminal domain substrate.Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin TTranscriptional activation in vitro by the human immunodeficiency virus type 1 Tat protein: evidence for specific interaction with a coactivator(s).Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site.Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm.Electrostatic interactions modulate the RNA-binding and transactivation specificities of the human immunodeficiency virus and simian immunodeficiency virus Tat proteinsTAR RNA binding properties and relative transactivation activities of human immunodeficiency virus type 1 and 2 Tat proteins.Protein interactions with DNA elements in variant equine infectious anemia virus enhancers and their impact on transcriptional activityEffects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding.Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanismThe ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat.Interactions between equine cyclin T1, Tat, and TAR are disrupted by a leucine-to-valine substitution found in human cyclin T1.Further characterization of equine foamy virus reveals unusual features among the foamy virusesTranscriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors.Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat.Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function.Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells.NMR analysis of the trans-activation response (TAR) RNA element of equine infectious anemia virus.Exosome-associated release, uptake, and neurotoxicity of HIV-1 Tat protein.Targeting tat inhibitors in the assembly of human immunodeficiency virus type 1 transcription complexes.
P2860
Q24315725-BD8AA344-7812-4F11-B6B8-6A29406C1714Q24523183-AA3A2520-3CD6-4DF2-8E14-B6E1184389C4Q24605302-FB05DCC3-792D-4FA2-B3B7-983C7ED8E7ADQ24605935-38B2BC6B-59B4-4901-A1B9-B4BE20617C93Q24632055-14169154-5479-4C96-9DAD-EFA785466BE3Q24646774-A130A62C-D330-41AC-A232-8499E4D66440Q24675484-8B8479EA-44C7-47F6-9CBC-02905C2BD1A8Q24676286-092D8254-ECB6-41D9-9B52-646A7FB6053DQ24682531-0CC63572-4AB6-41B2-80E2-279ED0C781E7Q24684723-789DD7FC-8917-495C-B6F4-9658F80FA740Q29614788-F8E90B38-C87A-4A2F-98C4-CC261035EE5AQ29620167-861FD27B-9CCD-497A-ABAE-89ABA1BFC129Q33815080-9D3BE10D-9897-49A8-8FDD-DFF2870B639EQ34987620-1A7CC1B7-C18B-4AC3-B150-510FA7409D02Q35782702-7B73028B-944A-49A2-8F68-609B5217EB3AQ35870516-50728B80-9EAB-465A-AA10-34AE8DDBB404Q35872597-83D8C3D9-749B-4245-9EFC-CE05A294F126Q36115020-7C48A58F-F89E-43D5-8E09-56570CD33189Q36642378-06AE98E2-C7FA-4F32-BA7B-E48F49FC38E4Q36654359-1DEDDA83-2AC9-4CE1-902F-1AD7BFD7B8C8Q38296024-5CC53612-BF9F-4C80-9BCC-24A649F51BD6Q39446082-09E1D2BE-DC23-4891-AEA8-6B4E2EB01F1FQ39580108-C7FD9BEC-B2D6-4BDB-AF21-CDEAF0A165FBQ39589026-C65DAD5C-4A62-4CCA-9DDC-3C6B830904ABQ39684100-A3D2DC26-FB22-42AD-B2B0-1F6ECF2A2E04Q39870080-616E70C6-E020-49EE-BED0-D5A49A9E0B8CQ39872155-61515125-A539-4493-969D-B1D1481B0B6AQ40045693-74C679DF-734C-4E99-9DC9-3B7E64D64ACCQ40066542-AF9A4901-073A-4B0B-AD38-F341681E0F3DQ40396291-FD9818FB-B6BE-4234-821C-88D5ABD760F5Q40676905-FDB5F98D-2725-4B68-8F51-36FC8308D0DAQ41973410-14E78B07-DE10-4301-9120-050D65CEF441
P2860
Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators.
description
1992 nî lūn-bûn
@nan
1992 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Inhibition of human immunodefi ...... heterologous trans activators.
@ast
Inhibition of human immunodefi ...... heterologous trans activators.
@en
type
label
Inhibition of human immunodefi ...... heterologous trans activators.
@ast
Inhibition of human immunodefi ...... heterologous trans activators.
@en
prefLabel
Inhibition of human immunodefi ...... heterologous trans activators.
@ast
Inhibition of human immunodefi ...... heterologous trans activators.
@en
P2093
P2860
P1433
P1476
Inhibition of human immunodefi ...... heterologous trans activators.
@en
P2093
P2860
P304
P407
P577
1992-04-01T00:00:00Z